| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 60 | 2024 | 409 | 6.690 |
Why?
|
| Brain | 41 | 2024 | 331 | 5.290 |
Why?
|
| Aging | 31 | 2023 | 352 | 3.790 |
Why?
|
| Cognition Disorders | 21 | 2018 | 237 | 2.930 |
Why?
|
| Aged, 80 and over | 67 | 2024 | 1034 | 2.730 |
Why?
|
| Cognition | 25 | 2024 | 337 | 2.530 |
Why?
|
| Cognitive Dysfunction | 17 | 2023 | 235 | 2.410 |
Why?
|
| Female | 77 | 2024 | 3346 | 2.300 |
Why?
|
| DNA-Binding Proteins | 12 | 2020 | 94 | 2.280 |
Why?
|
| Male | 75 | 2024 | 3399 | 2.220 |
Why?
|
| Aged | 67 | 2024 | 1860 | 2.200 |
Why?
|
| Humans | 98 | 2024 | 5837 | 2.150 |
Why?
|
| Dementia | 14 | 2023 | 127 | 1.960 |
Why?
|
| TDP-43 Proteinopathies | 6 | 2021 | 20 | 1.510 |
Why?
|
| Cerebral Amyloid Angiopathy | 5 | 2023 | 28 | 1.330 |
Why?
|
| Lewy Body Disease | 6 | 2020 | 29 | 1.330 |
Why?
|
| Cohort Studies | 26 | 2024 | 406 | 1.310 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2018 | 123 | 1.280 |
Why?
|
| Frontotemporal Lobar Degeneration | 2 | 2020 | 7 | 1.190 |
Why?
|
| Memory Disorders | 4 | 2018 | 48 | 1.160 |
Why?
|
| Longitudinal Studies | 26 | 2020 | 363 | 1.070 |
Why?
|
| Apolipoproteins E | 8 | 2021 | 55 | 0.970 |
Why?
|
| Genotype | 11 | 2018 | 114 | 0.910 |
Why?
|
| Parkinson Disease | 7 | 2017 | 134 | 0.900 |
Why?
|
| Plaque, Amyloid | 9 | 2023 | 29 | 0.900 |
Why?
|
| Cerebral Infarction | 7 | 2016 | 29 | 0.890 |
Why?
|
| Brain Infarction | 4 | 2018 | 23 | 0.880 |
Why?
|
| Neuropsychological Tests | 18 | 2020 | 309 | 0.860 |
Why?
|
| Hippocampus | 6 | 2019 | 61 | 0.770 |
Why?
|
| Genome-Wide Association Study | 11 | 2022 | 66 | 0.760 |
Why?
|
| Apolipoprotein E4 | 6 | 2018 | 92 | 0.740 |
Why?
|
| Cerebrovascular Disorders | 2 | 2021 | 19 | 0.730 |
Why?
|
| alpha-Synuclein | 3 | 2020 | 36 | 0.690 |
Why?
|
| Amyloid beta-Peptides | 11 | 2024 | 41 | 0.680 |
Why?
|
| Memory | 4 | 2018 | 61 | 0.660 |
Why?
|
| Temporal Lobe | 2 | 2018 | 17 | 0.650 |
Why?
|
| DNA Methylation | 8 | 2021 | 72 | 0.650 |
Why?
|
| Neurofibrillary Tangles | 9 | 2023 | 33 | 0.640 |
Why?
|
| Prospective Studies | 14 | 2022 | 411 | 0.590 |
Why?
|
| Autopsy | 12 | 2023 | 67 | 0.590 |
Why?
|
| Emergencies | 1 | 2019 | 18 | 0.570 |
Why?
|
| Lewy Bodies | 9 | 2019 | 56 | 0.550 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 8 | 0.550 |
Why?
|
| Hospitalization | 1 | 2019 | 86 | 0.550 |
Why?
|
| Genetic Variation | 5 | 2021 | 23 | 0.530 |
Why?
|
| Spinal Cord | 1 | 2017 | 23 | 0.530 |
Why?
|
| Neurodegenerative Diseases | 4 | 2021 | 39 | 0.520 |
Why?
|
| Independent Living | 5 | 2020 | 62 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2021 | 72 | 0.480 |
Why?
|
| Neuropathology | 4 | 2022 | 17 | 0.480 |
Why?
|
| Risk Factors | 14 | 2023 | 499 | 0.470 |
Why?
|
| Alleles | 9 | 2018 | 89 | 0.450 |
Why?
|
| Membrane Proteins | 5 | 2022 | 38 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 11 | 0.400 |
Why?
|
| Middle Aged | 12 | 2022 | 1775 | 0.400 |
Why?
|
| tau Proteins | 8 | 2023 | 36 | 0.380 |
Why?
|
| Disease Progression | 7 | 2019 | 157 | 0.380 |
Why?
|
| Nerve Tissue Proteins | 4 | 2022 | 52 | 0.370 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2020 | 21 | 0.360 |
Why?
|
| Tissue Donors | 1 | 2012 | 28 | 0.360 |
Why?
|
| Patient Selection | 1 | 2012 | 48 | 0.360 |
Why?
|
| Stroke | 3 | 2018 | 71 | 0.350 |
Why?
|
| Cerebral Hemorrhage | 3 | 2023 | 26 | 0.350 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 28 | 0.340 |
Why?
|
| Cerebral Cortex | 3 | 2021 | 36 | 0.340 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 24 | 0.330 |
Why?
|
| Folic Acid | 3 | 2006 | 10 | 0.300 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 187 | 0.300 |
Why?
|
| Logistic Models | 4 | 2017 | 109 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2023 | 207 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 9 | 0.290 |
Why?
|
| Vitamin B 12 | 2 | 2006 | 8 | 0.280 |
Why?
|
| Phenotype | 4 | 2021 | 96 | 0.280 |
Why?
|
| Dietary Supplements | 2 | 2006 | 18 | 0.280 |
Why?
|
| Membrane Transport Proteins | 3 | 2022 | 29 | 0.280 |
Why?
|
| Health Literacy | 2 | 2020 | 28 | 0.280 |
Why?
|
| Genome, Human | 2 | 2018 | 10 | 0.260 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 36 | 0.250 |
Why?
|
| Heterozygote | 2 | 2018 | 59 | 0.250 |
Why?
|
| Receptors, Immunologic | 2 | 2017 | 3 | 0.240 |
Why?
|
| Membrane Glycoproteins | 2 | 2017 | 18 | 0.240 |
Why?
|
| Parkinsonian Disorders | 2 | 2017 | 43 | 0.240 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 30 | 0.240 |
Why?
|
| Substantia Nigra | 1 | 2006 | 25 | 0.230 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2006 | 28 | 0.230 |
Why?
|
| Food, Fortified | 1 | 2005 | 3 | 0.220 |
Why?
|
| Genetic Association Studies | 5 | 2018 | 32 | 0.220 |
Why?
|
| United States | 6 | 2019 | 502 | 0.210 |
Why?
|
| Genetic Loci | 2 | 2014 | 16 | 0.210 |
Why?
|
| Sclerosis | 4 | 2019 | 26 | 0.210 |
Why?
|
| Amyloid | 3 | 2021 | 6 | 0.210 |
Why?
|
| Aniline Compounds | 3 | 2013 | 10 | 0.210 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 21 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 10 | 0.190 |
Why?
|
| DNA | 1 | 2003 | 38 | 0.190 |
Why?
|
| Memory, Short-Term | 2 | 2022 | 37 | 0.190 |
Why?
|
| Flavonols | 1 | 2022 | 5 | 0.190 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 66 | 0.190 |
Why?
|
| Proteomics | 2 | 2022 | 10 | 0.190 |
Why?
|
| Transcriptome | 2 | 2019 | 12 | 0.180 |
Why?
|
| Gene Expression | 3 | 2019 | 64 | 0.180 |
Why?
|
| Ethylene Glycols | 2 | 2012 | 2 | 0.180 |
Why?
|
| Adult | 6 | 2021 | 1670 | 0.180 |
Why?
|
| Gait | 1 | 2023 | 93 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2022 | 9 | 0.180 |
Why?
|
| Memory, Episodic | 2 | 2019 | 26 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 30 | 0.180 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2021 | 1 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2021 | 1 | 0.180 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 16 | 0.170 |
Why?
|
| Microglia | 3 | 2017 | 25 | 0.170 |
Why?
|
| Neuropeptides | 2 | 2020 | 12 | 0.170 |
Why?
|
| Iron | 1 | 2021 | 6 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 1 | 0.170 |
Why?
|
| Microcirculation | 3 | 2011 | 13 | 0.170 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 24 | 0.170 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 17 | 0.170 |
Why?
|
| Limbic Encephalitis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Proteins | 1 | 2020 | 22 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2020 | 10 | 0.160 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 41 | 0.160 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 3 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 333 | 0.160 |
Why?
|
| Mental Status Schedule | 2 | 2018 | 32 | 0.160 |
Why?
|
| Arteriolosclerosis | 2 | 2018 | 14 | 0.160 |
Why?
|
| Frontal Lobe | 2 | 2018 | 17 | 0.160 |
Why?
|
| LDL-Receptor Related Proteins | 2 | 2022 | 6 | 0.160 |
Why?
|
| Mutation | 1 | 2020 | 101 | 0.160 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 26 | 0.150 |
Why?
|
| SNARE Proteins | 1 | 2019 | 1 | 0.150 |
Why?
|
| Synapses | 1 | 2019 | 6 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 9 | 0.150 |
Why?
|
| Age Factors | 5 | 2015 | 181 | 0.150 |
Why?
|
| RNA, Messenger | 2 | 2017 | 87 | 0.150 |
Why?
|
| HIV Infections | 1 | 2020 | 135 | 0.140 |
Why?
|
| Medicare | 1 | 2019 | 30 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 71 | 0.140 |
Why?
|
| E2F Transcription Factors | 1 | 2018 | 1 | 0.140 |
Why?
|
| Estradiol | 1 | 2018 | 12 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 3 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2018 | 36 | 0.140 |
Why?
|
| Linear Models | 1 | 2018 | 64 | 0.140 |
Why?
|
| Learning | 1 | 2018 | 23 | 0.130 |
Why?
|
| Cognitive Aging | 1 | 2018 | 27 | 0.130 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 7 | 0.130 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 2 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 30 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2017 | 13 | 0.130 |
Why?
|
| Gene Frequency | 2 | 2017 | 21 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 8 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 15 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Peptide Fragments | 2 | 2014 | 15 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 64 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 22 | 0.120 |
Why?
|
| Postmortem Changes | 1 | 2016 | 9 | 0.120 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 2 | 2013 | 3 | 0.120 |
Why?
|
| White Matter | 1 | 2016 | 24 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 26 | 0.120 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 2 | 0.120 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 2 | 0.120 |
Why?
|
| Educational Status | 2 | 2017 | 60 | 0.120 |
Why?
|
| Receptors, Complement 3b | 2 | 2016 | 8 | 0.110 |
Why?
|
| Awareness | 1 | 2015 | 13 | 0.110 |
Why?
|
| Organ Size | 1 | 2015 | 16 | 0.110 |
Why?
|
| Linkage Disequilibrium | 3 | 2017 | 11 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2015 | 1 | 0.110 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 3 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2015 | 3 | 0.110 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 6 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2017 | 136 | 0.110 |
Why?
|
| Animals | 4 | 2019 | 1349 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2017 | 60 | 0.110 |
Why?
|
| Incidence | 4 | 2018 | 165 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 284 | 0.110 |
Why?
|
| CpG Islands | 3 | 2021 | 21 | 0.110 |
Why?
|
| Quality of Life | 1 | 2015 | 108 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 4 | 0.100 |
Why?
|
| Dementia, Vascular | 2 | 2018 | 7 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 14 | 0.100 |
Why?
|
| Synucleins | 1 | 2013 | 2 | 0.100 |
Why?
|
| Fatty Acids | 2 | 2018 | 13 | 0.100 |
Why?
|
| Neurites | 1 | 2012 | 1 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 9 | 0.090 |
Why?
|
| Research Design | 1 | 2012 | 42 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 19 | 0.090 |
Why?
|
| Haplotypes | 2 | 2020 | 19 | 0.090 |
Why?
|
| Cognitive Reserve | 1 | 2011 | 2 | 0.090 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 1 | 0.090 |
Why?
|
| Receptor, EphA1 | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 4 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 28 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2011 | 12 | 0.080 |
Why?
|
| Olfaction Disorders | 1 | 2011 | 8 | 0.080 |
Why?
|
| Comorbidity | 3 | 2018 | 98 | 0.080 |
Why?
|
| Neocortex | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 4 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 11 | 0.070 |
Why?
|
| Depression | 2 | 2021 | 113 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 10 | 0.070 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2007 | 1 | 0.060 |
Why?
|
| Algorithms | 1 | 2007 | 82 | 0.060 |
Why?
|
| Loneliness | 1 | 2007 | 22 | 0.060 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 3 | 0.060 |
Why?
|
| Trans Fatty Acids | 1 | 2006 | 4 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 11 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2006 | 19 | 0.060 |
Why?
|
| Cell Count | 2 | 2021 | 16 | 0.060 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 59 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2022 | 584 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 48 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Data Collection | 1 | 2005 | 15 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2005 | 36 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 110 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 71 | 0.050 |
Why?
|
| Neurons | 2 | 2018 | 90 | 0.050 |
Why?
|
| Chicago | 1 | 2005 | 239 | 0.050 |
Why?
|
| Hand Strength | 1 | 2023 | 11 | 0.050 |
Why?
|
| Age of Onset | 2 | 2014 | 27 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2003 | 1 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pan troglodytes | 1 | 2003 | 2 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2017 | 22 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 13 | 0.050 |
Why?
|
| Quercetin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Kaempferols | 1 | 2022 | 5 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2003 | 13 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 53 | 0.050 |
Why?
|
| Eating | 1 | 2022 | 16 | 0.050 |
Why?
|
| Infant | 1 | 2023 | 184 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 141 | 0.050 |
Why?
|
| Proteome | 1 | 2022 | 2 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 4 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2013 | 37 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 8 | 0.040 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 4 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 5 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 6 | 0.040 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 17 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 94 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2020 | 5 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 10 | 0.040 |
Why?
|
| Lysosomes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 2020 | 2 | 0.040 |
Why?
|
| Risk | 2 | 2015 | 60 | 0.040 |
Why?
|
| HIV-1 | 1 | 2020 | 74 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 112 | 0.040 |
Why?
|
| Nerve Net | 1 | 2019 | 18 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2019 | 22 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 32 | 0.040 |
Why?
|
| Metabolome | 1 | 2018 | 2 | 0.040 |
Why?
|
| Metabolomics | 1 | 2018 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 1 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 2 | 0.040 |
Why?
|
| DNA Repair | 1 | 2018 | 2 | 0.040 |
Why?
|
| Reproduction | 1 | 2018 | 2 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 11 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 9 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2018 | 5 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 21 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2018 | 5 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 54 | 0.030 |
Why?
|
| Astrocytes | 1 | 2018 | 23 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 11 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 203 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 13 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2017 | 2 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 4 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 11 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 46 | 0.030 |
Why?
|
| Diagnosis | 1 | 2017 | 5 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 34 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2017 | 4 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 10 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 71 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 8 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 13 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 138 | 0.030 |
Why?
|
| Chromatin | 1 | 2016 | 7 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 53 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 189 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 10 | 0.030 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2015 | 1 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 4 | 0.030 |
Why?
|
| Maze Learning | 1 | 2015 | 3 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 8 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 5 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 13 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 23 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2015 | 43 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 122 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 5 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 22 | 0.030 |
Why?
|
| Time Factors | 1 | 2015 | 374 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 18 | 0.020 |
Why?
|
| Dextrans | 1 | 2013 | 1 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 1 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 2 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 465 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 54 | 0.020 |
Why?
|
| Autoradiography | 1 | 2012 | 3 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 125 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 19 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 421 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2011 | 1 | 0.020 |
Why?
|
| Social Environment | 1 | 2011 | 9 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2011 | 20 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 2 | 0.020 |
Why?
|
| Multigene Family | 1 | 2011 | 3 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 67 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 103 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 57 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2011 | 31 | 0.020 |
Why?
|
| Child | 1 | 2011 | 339 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 2 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 11 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2008 | 2 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 30 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Microtubules | 1 | 2007 | 8 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 37 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 35 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2007 | 31 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 12 | 0.020 |
Why?
|
| Social Isolation | 1 | 2007 | 9 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 9 | 0.020 |
Why?
|
| Diet | 1 | 2006 | 54 | 0.010 |
Why?
|